Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915885 | 0.91 | SLC9A1 (0.46) | SLC9A1HCAR3CYP19A1ICMT | |
| SCHEMBL19848164 | 0.90 | SLC9A1 (0.45) | SLC9A1HCAR3CYP19A1TDO2 | |
| SCHEMBL19915671 | 0.89 | SLC9A1 (0.41) | SLC9A1CYP19A1ICMTTSHRPLA2G4A | |
| SCHEMBL19848442 | 0.85 | SLC9A1 (0.57) | SLC9A1HCAR3TSHRGLA | |
| SCHEMBL19911498 | 0.83 | SLC9A1 (0.50) | SLC9A1HCAR3TDO2 | |
| SCHEMBL19915656 | 0.82 | SLC9A1 (0.55) | SLC9A1HCAR3TSHRGLA | |
| SCHEMBL19911605 | 0.82 | SLC9A1 (0.49) | SLC9A1HCAR3TDO2PLA2G4A | |
| SCHEMBL19911630 | 0.82 | SLC9A1 (0.49) | SLC9A1HCAR3ICMTTDO2 | |
| SCHEMBL19915887 | 0.80 | SLC9A1 (0.41) | SLC9A1HCAR3CYP19A1ICMTTSHR | |
| SCHEMBL19911528 | 0.80 | SLC9A1 (0.47) | SLC9A1HCAR3PLA2G4AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885CYP19A1 3005/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885HCAR3 4636/4885CYP19A1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.